GlycoMimetics, Inc. (GLYC) |
|
0.6156 -0.046 (-6.9%)
|
06-26 22:44 |
|
Open: |
0.676 |
Pre. Close: |
0.6612 |
|
High:
|
0.676 |
Low:
|
0.6156 |
|
Volume:
|
151,955 |
Market Cap:
|
32(M) |
|
|
|
|
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.68 - 0.68 |
0.68 - 0.68 |
|
Low:
|
0.61 - 0.61 |
0.61 - 0.61 |
|
Close:
|
0.61 - 0.62 |
0.62 - 0.62 |
|
Technical analysis |
as of: 2022-06-24 4:40:19 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.76 One year: 0.86 |
| Support: |
Support1: 0.5 Support2: 0.42 |
| Resistance: |
Resistance1: 0.65 Resistance2: 0.74 |
| Pivot: |
0.62 |
| Moving Average: |
MA(5): 0.63 MA(20): 0.63
MA(100): 0.89 MA(250): 1.47 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 53.8 %D(3): 53.5 |
| RSI: |
RSI(14): 46.5 |
| 52-week: |
High: 2.5 Low: 0.5 |
| Average Vol(K): |
3-Month: 189 (K) 10-Days: 222 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GLYC ] has closed above bottom band by 45.4%. Bollinger Bands are 44.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sat, 18 Jun 2022
Stock Analysts' New Coverage for June 18th (AAMC, AAU, ABIO, AHPI, BIOL, CERN, FB, GALT, GLYC, JOB) - Defense World
Sat, 18 Jun 2022
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Fri, 10 Jun 2022
GlycoMimetics (NASDAQ:GLYC) Earns Hold Rating from Analysts at StockNews.com - Defense World
Sat, 04 Jun 2022
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely - Simply Wall St
Fri, 03 Jun 2022
A GlycoMimetics, Inc. (NASDAQ:GLYC) insider increased their holdings last year - Yahoo Eurosport UK
Thu, 02 Jun 2022
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
52 (M) |
|
% Held by Insiders
|
3.263e+007 (%) |
|
% Held by Institutions
|
1.9 (%) |
|
Shares Short
|
605 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-6.357e+007 |
|
EPS Est Next Qtl
|
-0.29 |
|
EPS Est This Year
|
-1.22 |
|
EPS Est Next Year
|
-0.94 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-61 |
|
Return on Assets (ttm)
|
180.7 |
|
Return on Equity (ttm)
|
-36.4 |
|
Qtrly Rev. Growth
|
104330 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-34.24 |
|
EBITDA (p.s.)
|
601036 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-57 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
0.91 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
613660 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
